BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld MedTech
Home
» Med tech M&A values flail; COVID-19 diagnostic deal largest for year
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Q2 deals and M&As
Med tech M&A values flail; COVID-19 diagnostic deal largest for year
July 17, 2020
By
Karen Carey
No Comments
While med-tech dealmaking in the second quarter of 2020 increased by 27% from the first quarter and is in line with the values disclosed during the same period in 2019, M&A money for the industry has fallen significantly.
BioWorld MedTech
Analysis and data insight
Deals and M&A